131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases

NCT03275402 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

52

Enrollment

INDUSTRY

Sponsor class

Stopped Corporate business decision. Not due to safety or efficacy concerns.

Conditions

Neuroblastoma
CNS Metastases
Leptomeningeal Metastases

Interventions

BIOLOGICAL: 131I-omburtamab

Sponsor

Y-mAbs Therapeutics